{
  "meta": {
    "title": "Obstructive_Lung_Diseases",
    "url": "https://brainandscalpel.vercel.app/obstructive-lung-diseases-14050a2f.html",
    "scrapedAt": "2025-11-29T18:25:15.428Z"
  },
  "questions": [
    {
      "id": 11218,
      "choices": [
        {
          "id": 44838,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC &lt;0.7 and FEV1 &lt; 30%</span></span></span></span></p>"
        },
        {
          "id": 44839,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC &lt;0.7 and FEV1 &lt;70%</span></span></span></span></p>"
        },
        {
          "id": 44840,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC&lt;0.7 and FEV1&lt; 50%</span></span></span></span></p>"
        },
        {
          "id": 44841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both A and C</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Gold&#39;s criteria for very severe COPD is:</span></span> <span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></p>",
      "unique_key": "Q4486056",
      "question_audio": null,
      "question_video": null,
      "map_id": 20076,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) FEV1/FVC &lt;0.7 and FEV1 &lt; 30%</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for staging chronic obstructive pulmonary disease (COPD), very severe COPD is classified as Stage IV. This stage is defined by a FEV1/FVC ratio (forced expiratory volume in one second/forced vital capacity) less than 0.7, which indicates the presence of airflow limitation, and a FEV1 less than 30% of the predicted value. This level of FEV1 signifies a very severe reduction in lung function and typically corresponds with significant symptoms and health status impairment.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-164040.jpg\" style=\"height:335px; width:992px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Currently Class C+D have been combined and called Class E</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Classification of types have been updated.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference: GOLD 2023 guidelines</span></span></em></strong></p>",
      "correct_choice_id": 44838,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20114,
      "choices": [
        {
          "id": 80417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exposure to cat dander</span></span></span></p>"
        },
        {
          "id": 80418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent URI with rhinovirus </span></span></span></p>"
        },
        {
          "id": 80419,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Using beta-blocker for hypertension </span></span></span></p>"
        },
        {
          "id": 80420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consuming large amounts of alcohol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 48-year-old man with a history of asthma presents to the clinic with worsening wheezing, cough, and shortness of breath. Which of the following is the LEAST likely trigger for his current exacerbation?</span></span></span></p>",
      "unique_key": "Q4775977",
      "question_audio": null,
      "question_video": null,
      "map_id": 20067,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>D)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Consuming large amounts of alcohol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While excessive alcohol consumption can indirectly worsen asthma symptoms through dehydration or disrupted sleep, it is not a direct trigger for bronchoconstriction and airway inflammation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Triggers for airway narrowing in asthma: 1. Allergens 2. Irritants 3. Viral infections 4. Exercise and cold, dry air 5. Air pollution 6. Drugs 7. Occupational exposures 8. Hormonal changes 9. Pregnancy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Exposure to cat dander:</span></strong><span style=\"font-size:12.0pt\"> Animal dander is a common allergen and a well-known trigger for asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options B. Recent URI with rhinovirus:</span></strong><span style=\"font-size:12.0pt\"> Viral respiratory infections are among the most common triggers of asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options C. Using a beta-blocker for hypertension:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Beta-blockers can worsen asthma symptoms due to their bronchoconstrictive effects by blocking beta-2 receptors in the airways.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcohol consumption is not a direct trigger for bronchoconstriction and airway inflammation in asthma.</span></span></span></p>",
      "correct_choice_id": 80420,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20115,
      "choices": [
        {
          "id": 80421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFTR </span></span></span></p>"
        },
        {
          "id": 80422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 </span></span></span></p>"
        },
        {
          "id": 80423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ORMDL3 </span></span></span></p>"
        },
        {
          "id": 80424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">KCNH2</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old boy with a family history of asthma and allergies presents with recurrent wheezing, coughing, and shortness of breath. Genetic testing is being considered to assess his risk of developing persistent asthma. Which of the following genes is MOST consistently associated with asthma susceptibility?</span></span></p>",
      "unique_key": "Q3653607",
      "question_audio": null,
      "question_video": null,
      "map_id": 20068,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) ORMDL3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ORMDL3 is one of the most consistently identified genes associated with asthma susceptibility, particularly in early-onset disease. It is involved in airway remodeling and inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Asssociated genes in asthma:</span></strong> <em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">The most consistently identified include&nbsp;</span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">ORMDL3/GSDMB </span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">(in the 17q21 chromosomal region),&nbsp;</span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">ADAM33</span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">, DPP-10, </span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">TSLP</span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">, IL-12, IL-33, ST2, HLA-DQB1, HLA-DQB2, TLR1, and IL6R.</span></em></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. CFTR:</span></strong><span style=\"font-size:12.0pt\"> Associated with cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options B. BRCA1:</span></strong><span style=\"font-size:12.0pt\"> Associated with breast and ovarian cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options D. KCNH2:</span></strong><span style=\"font-size:12.0pt\"> Associated with long QT syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ORMDL3 is the most <strong>&nbsp;</strong>consistently associated gene with asthma susceptibility. </span></span></p>",
      "correct_choice_id": 80423,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20116,
      "choices": [
        {
          "id": 80425,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised serum IgE levels </span></span></span></p>"
        },
        {
          "id": 80426,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive skin test for inhaled allergens </span></span></span></p>"
        },
        {
          "id": 80427,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nasal polyps </span></span></span></p>"
        },
        {
          "id": 80428,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A type of extrinsic asthma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old woman experiences recurrent episodes of wheezing and nasal congestion after taking aspirin for a headache. Which of the following is most likely associated with her condition?</span></span></p>",
      "unique_key": "Q4909850",
      "question_audio": null,
      "question_video": null,
      "map_id": 20069,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Nasal polyps</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of asthma, aspirin sensitivity, and nasal polyps is characteristic of aspirin-exacerbated respiratory disease (AERD) &ndash; previously called as Samters triad. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Raised serum IgE levels:</span></strong><span style=\"font-size:12.0pt\"> Associated with allergic asthma, not AERD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Positive skin test for inhaled allergens:</span></strong><span style=\"font-size:12.0pt\"> Also associated with allergic asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. A type of extrinsic asthma:</span></strong><span style=\"font-size:12.0pt\"> AERD is a type of intrinsic (non-allergic) asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nasal polyps are characteristic of aspirin-exacerbated respiratory disease (AERD) in patients with asthma and aspirin sensitivity.</span></span></span></p>",
      "correct_choice_id": 80427,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20118,
      "choices": [
        {
          "id": 80433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest X-ray </span></span></span></p>"
        },
        {
          "id": 80434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin prick test </span></span></span></p>"
        },
        {
          "id": 80435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FEV1 measurement </span></span></span></p>"
        },
        {
          "id": 80436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demonstration of reversible obstruction on PFT</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient experiences recurrent episodes of wheezing, cough, and shortness of breath. Which test is most reliable in confirming the diagnosis of bronchial asthma?</span></span></span></p>",
      "unique_key": "Q3520325",
      "question_audio": null,
      "question_video": null,
      "map_id": 20070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Demonstration of reversible obstruction on PFT</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A significant improvement in FEV1 after bronchodilator administration on PFTs is the most reliable indicator of reversible airflow obstruction, the hallmark of asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chest X-ray:</span></strong><span style=\"font-size:12.0pt\"> Typically normal in asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Skin prick test:</span></strong><span style=\"font-size:12.0pt\"> Identifies allergic triggers, but not diagnostic of asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. FEV1 measurement:</span></strong><span style=\"font-size:12.0pt\"> May show obstruction, but reversibility is key for diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demonstration of reversible obstruction on PFTs is the most reliable test for confirming the diagnosis of bronchial asthma.</span></span></span></p>",
      "correct_choice_id": 80436,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20119,
      "choices": [
        {
          "id": 80437,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 minutes </span></span></p>"
        },
        {
          "id": 80438,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">15 minutes </span></span></p>"
        },
        {
          "id": 80439,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30 minutes </span></span></span></p>"
        },
        {
          "id": 80440,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">60 minutes</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After administering a short-acting beta-agonist (SABA) inhaler like salbutamol for suspected asthma, how long should you wait before repeating spirometry to assess for reversibility?</span></span></p>",
      "unique_key": "Q7995772",
      "question_audio": null,
      "question_video": null,
      "map_id": 20071,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 15 minutes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The bronchodilator effect of SABAs like salbutamol typically peaks around 15 minutes after administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>5 minutes:</strong> Too soon; the full effect of the bronchodilator may not yet be evident.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"><strong>&nbsp;30 minutes and,&nbsp;</strong></span><strong><span style=\"font-size:12.0pt\">D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>60 minutes</strong>: Waiting longer may lead to the bronchodilator effect wearing off, giving a false negative result.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wait 15 minutes after administering a SABA inhaler like salbutamol before repeating spirometry to assess for reversibility.</span></span></p>",
      "correct_choice_id": 80438,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20122,
      "choices": [
        {
          "id": 80449,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Improved survival </span></span></p>"
        },
        {
          "id": 80450,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced pulmonary vascular resistance </span></span></p>"
        },
        {
          "id": 80451,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased hematocrit </span></span></p>"
        },
        {
          "id": 80452,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Improved V/Q mismatch</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with stable COPD and resting oxygen saturation of 88% on room air is started on long-term oxygen therapy (LTOT). Which of the following is NOT a known benefit of LTOT in COPD?</span></span></span></p>",
      "unique_key": "Q3337231",
      "question_audio": null,
      "question_video": null,
      "map_id": 20072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased hematocrit</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term oxygen therapy (LTOT) in COPD patients with chronic hypoxemia (resting SpO2 &le; 88%) has several established benefits:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Improved survival:</span></strong><span style=\"font-size:12.0pt\"> LTOT has been shown to increase survival in patients with severe resting hypoxemia (PaO2 &le; 55 mmHg).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reduced pulmonary vascular resistance:</span></strong><span style=\"font-size:12.0pt\"> LTOT helps reduce pulmonary hypertension by improving oxygenation and decreasing hypoxic vasoconstriction.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Improved V/Q mismatch:</span></strong><span style=\"font-size:12.0pt\"> By increasing alveolar oxygen tension, LTOT can help correct the ventilation-perfusion mismatch often seen in COPD.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Decreased hematocrit (polycythemia):</span></strong><span style=\"font-size:12.0pt\"> Chronic hypoxemia can trigger an increase in red blood cell production (polycythemia). LTOT can reverse this effect</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long-term oxygen therapy (LTOT) in COPD improves survival, reduces pulmonary vascular resistance, and improves V/Q mismatch, but it does not increase hematocrit.</span></span></p>",
      "correct_choice_id": 80451,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20130,
      "choices": [
        {
          "id": 80481,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 of 54 mmHg and evidence of cor pulmonale </span></span></span></p>"
        },
        {
          "id": 80482,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 88% on room air and a history of two COPD exacerbations in the past year </span></span></span></p>"
        },
        {
          "id": 80483,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 of 58 mmHg and a hematocrit of 55% </span></span></span></p>"
        },
        {
          "id": 80484,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 89% and a normal 6-minute walk distance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old man with severe emphysema secondary to alpha-1 antitrypsin deficiency is being evaluated for long-term oxygen therapy (LTOT). Which of the following scenarios would NOT meet the criteria for LTOT in this patient?</span></span></span></p>",
      "unique_key": "Q3286144",
      "question_audio": null,
      "question_video": null,
      "map_id": 20073,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Resting SpO2 of 89% and a normal 6-minute walk distance</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The current guidelines for LTOT in COPD recommend it for patients with:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 &le; 55 mmHg OR SaO2 &le; 88% on room air</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">OR PaO2 56-59 mmHg or SaO2 89% with evidence of:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cor pulmonale</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycythemia (Hct &gt; 55%)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hypertension</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D.</strong>&nbsp;does not meet these criteria as the patient&#39;s oxygen saturation is above 88% and there&#39;s no evidence of end-organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Resting PaO2 of 54 mmHg and evidence of cor pulmonale:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria for LTOT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Resting SpO2 of 88% and a history of two COPD exacerbations:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria due to low SpO2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Resting PaO2 of 58 mmHg and a hematocrit of 55%:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria due to low PaO2 and high hematocrit</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 89% and a normal 6-minute walk distance do not meet the criteria for long-term oxygen therapy (LTOT) in COPD.</span></span></span></p>",
      "correct_choice_id": 80484,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20134,
      "choices": [
        {
          "id": 80497,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tiotropium </span></span></span></p>"
        },
        {
          "id": 80498,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Salmeterol </span></span></span></p>"
        },
        {
          "id": 80499,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Roflumilast </span></span></span></p>"
        },
        {
          "id": 80500,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with severe COPD and chronic bronchitis presents with a history of frequent exacerbations despite optimal bronchodilator therapy. He has a 50-pack-year smoking history and continues to smoke 1 pack per day. Which of the following medications is most likely to reduce the frequency of his exacerbations?</span></span></span></p>",
      "unique_key": "Q4280509",
      "question_audio": null,
      "question_video": null,
      "map_id": 20074,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Roflumilast&nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roflumilast is specifically indicated for severe COPD with chronic bronchitis and frequent exacerbations despite optimized bronchodilator therapy. It works by reducing inflammation and mucus production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tiotropium:</span></strong><span style=\"font-size:12.0pt\"> While a LAMA improves lung function and symptoms, it doesn&#39;t have the same impact on exacerbation frequency as roflumilast.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Salmeterol:</span></strong><span style=\"font-size:12.0pt\"> LABAs improve lung function but don&#39;t specifically target exacerbations like roflumilast.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisolone:</span></strong><span style=\"font-size:12.0pt\"> Oral steroids are used for acute exacerbations, not long-term prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Roflumilast (PDE4 inhibitor) is indicated for severe COPD with chronic bronchitis and frequent exacerbations, reducing inflammation and mucus production.</span></span></span></p>",
      "correct_choice_id": 80499,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20139,
      "choices": [
        {
          "id": 80517,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD A </span></span></span></p>"
        },
        {
          "id": 80518,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD B </span></span></span></p>"
        },
        {
          "id": 80519,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD C </span></span></span></p>"
        },
        {
          "id": 80520,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD E</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old smoker with a history of COPD presents to the clinic with a COPD Assessment Test (CAT) score of 15 and two hospitalizations for COPD exacerbations in the past year. Which GOLD category does he belong to based on the 2023 GOLD guidelines?</span></span></span></p>",
      "unique_key": "Q8846498",
      "question_audio": null,
      "question_video": null,
      "map_id": 20075,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) GOLD E</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The 2023 GOLD guidelines have replaced categories C and D with category E. Group E patients have a high symptom burden (CAT score &ge;10) or history of exacerbations, regardless of airflow limitation severity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture41.jpg\" style=\"height:392px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GOLD A:</span></strong><span style=\"font-size:12.0pt\"> Low risk, low symptoms</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GOLD B:</span></strong><span style=\"font-size:12.0pt\"> Low risk, high symptoms</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GOLD C:</span></strong><span style=\"font-size:12.0pt\"> No longer used in the 2023 guidelines</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with a high symptom burden (CAT score &ge;10) or a history of exacerbations belong to GOLD category E according to the 2023 GOLD guidelines.</span></span></p>",
      "correct_choice_id": 80520,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20145,
      "choices": [
        {
          "id": 80541,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased total lung capacity (TLC) </span></span></span></p>"
        },
        {
          "id": 80542,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased FEV1/FVC ratio </span></span></span></p>"
        },
        {
          "id": 80543,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased diffusing capacity of the lung for carbon monoxide (DLCO) </span></span></span></p>"
        },
        {
          "id": 80544,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased vital capacity (VC)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with a long history of smoking and progressive dyspnea presents with a barrel chest and expiratory wheezing. Which of the following pulmonary function test (PFT) findings is NOT typically seen in emphysema?</span></span></p>",
      "unique_key": "Q5255031",
      "question_audio": null,
      "question_video": null,
      "map_id": 20078,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Increased diffusing capacity of the lung for carbon monoxide (DLCO)</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Emphysema destroys alveoli, leading to decreased gas exchange surface area and a <em>reduced</em> DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased total lung capacity (TLC)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Common in emphysema due to air trapping and hyperinflation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased FEV1/FVC ratio:</span></strong><span style=\"font-size:12.0pt\"> Hallmark of obstructive lung disease like emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased vital capacity (VC):</span></strong><span style=\"font-size:12.0pt\"> Often seen in emphysema due to severe air trapping - also called as &lsquo;pseudo-restriction&rsquo;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased DLCO is not typically seen in emphysema, as this condition reduces gas exchange surface area, leading to decreased DLCO.</span></span></span></p>",
      "correct_choice_id": 80543,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20147,
      "choices": [
        {
          "id": 80549,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 1 (Mild) </span></span></span></p>"
        },
        {
          "id": 80550,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 2 (Moderate) </span></span></span></p>"
        },
        {
          "id": 80551,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 3 (Severe) </span></span></span></p>"
        },
        {
          "id": 80552,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 4 (Very Severe)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with severe COPD undergoes spirometry after bronchodilator administration. His FEV1 is 28% of the predicted value. Which GOLD stage does he belong to?</span></span></span></p>",
      "unique_key": "Q3867532",
      "question_audio": null,
      "question_video": null,
      "map_id": 20080,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) GOLD 4 (Very Severe)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Very severe COPD (GOLD 4) is defined by a post-bronchodilator FEV1 less than 30% of the predicted value.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GOLD 1&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Mild)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">FEV1 &ge; 80% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GOLD 2 (</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Moderate)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>:&nbsp;</strong>50% &le; FEV1 &lt; 80% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GOLD 3 </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Severe)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">30% &le; FEV1 &lt; 50% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Very severe COPD (GOLD 4) is defined by a post-bronchodilator FEV1 less than 30% of the predicted value.</span></span></span></p>",
      "correct_choice_id": 80552,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20149,
      "choices": [
        {
          "id": 80557,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 0 </span></span></span></p>"
        },
        {
          "id": 80558,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 1 </span></span></span></p>"
        },
        {
          "id": 80559,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 2 </span></span></span></p>"
        },
        {
          "id": 80560,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 3</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 62-year-old woman with COPD reports that she becomes short of breath when walking at her own pace on level ground, and sometimes has to stop for breath. Based on the modified Medical Research Council (mMRC) dyspnea scale, what is her dyspnea grade?</span></span></span></p>",
      "unique_key": "Q2675997",
      "question_audio": null,
      "question_video": null,
      "map_id": 20082,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) mMRC 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s description matches the mMRC grade 2 criterion: &quot;Short of breath when hurrying on the level or walking up a slight hill.&quot;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. mMRC 0:</span></strong><span style=\"font-size:12.0pt\">&nbsp;No breathlessness except with strenuous exercise.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. mMRC 1:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Breathlessness when hurrying or walking up a slight hill.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mMRC 3:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Walks slower than others of same age due to breathlessness or stops for breath at own pace.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s description matches the mMRC grade 2 criterion: &quot;Short of breath when hurrying on the level or walking up a slight hill.&quot;</span></span></p>",
      "correct_choice_id": 80559,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20150,
      "choices": [
        {
          "id": 80561,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Body mass index (BMI) </span></span></span></p>"
        },
        {
          "id": 80562,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Airflow obstruction (FEV1) </span></span></span></p>"
        },
        {
          "id": 80563,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dyspnea (mMRC grade) </span></span></span></p>"
        },
        {
          "id": 80564,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exacerbation frequency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT a component of the BODE index, a prognostic tool in COPD that incorporates the mMRC dyspnea scale?</span></span></span></p>",
      "unique_key": "Q8742861",
      "question_audio": null,
      "question_video": null,
      "map_id": 20083,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Exacerbation frequency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BODE index includes BMI, airflow obstruction (FEV1), dyspnea (mMRC grade), and exercise capacity (6-minute walk distance). Exacerbation frequency, while important, is not included in the BODE index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BMI:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Lower BMI is associated with worse prognosis in COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Airflow obstruction (FEV1):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Lower FEV1 indicates worse lung function and prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dyspnea (mMRC grade):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Higer mMRC grade indicates more severe dyspnea and worse prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exacerbation frequency, while important, is not included in the BODE index, which incorporates BMI, FEV1, mMRC dyspnea grade, and 6-minute walk distance.</span></span></span></p>",
      "correct_choice_id": 80564,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20151,
      "choices": [
        {
          "id": 80565,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asthma </span></span></span></p>"
        },
        {
          "id": 80566,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD (Chronic Obstructive Pulmonary Disease) </span></span></span></p>"
        },
        {
          "id": 80567,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allergic Bronchopulmonary Aspergillosis (ABPA) </span></span></span></p>"
        },
        {
          "id": 80568,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary Langerhans Cell Histiocytosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a 20-pack-year smoking history presents with progressive shortness of breath and chronic cough. Spirometry reveals an FEV1 of 62% predicted and an FEV1/FVC ratio of 39%. After administration of a bronchodilator (BD), the FEV1 improves to 75% predicted, and the FEV1/FVC ratio improves to 73%. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2168756",
      "question_audio": null,
      "question_video": null,
      "map_id": 20084,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Asthma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post BD FEV1/FVC &gt; 70% rules out COPD and establishes the diagnosis of asthma. Note that this patient also has a significant improvement in FEV1 post bronchodilator (FEV1 &ge; 12%/200mL)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. COPD&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Chronic Obstructive Pulmonary Disease)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Although COPD can also cause airflow obstruction, it is typically less reversible with bronchodilators.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Allergic Bronchopulmonary Aspergillosis (ABPA)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> While ABPA can cause asthma-like symptoms, it is usually associated with elevated IgE levels and positive Aspergillus serology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pulmonary Langerhans Cell Histiocytosis:</span></strong><span style=\"font-size:12.0pt\"> Primarily seen in smokers and associated with cystic lung lesions on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-bronchodilator FEV1/FVC &gt; 70% rules out COPD and establishes the diagnosis of asthma, with significant improvement in FEV1 indicating reversibility.</span></span></span></p>",
      "correct_choice_id": 80565,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20152,
      "choices": [
        {
          "id": 80569,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Irreversible airflow limitation </span></span></span></p>"
        },
        {
          "id": 80570,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased residual volume (RV) </span></span></span></p>"
        },
        {
          "id": 80571,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Affects small airways </span></span></span></p>"
        },
        {
          "id": 80572,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can occur due to protease-antiprotease imbalance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old smoker with a long-standing history of dyspnea and a scanty cough experiences relief with bronchodilator therapy. Pulmonary function tests reveal an FEV1/FVC 54% and FEV1 50% predicted. Post Bronchodilator neb his FEV1/FVC improved to 65% and FEV1 improved to 57%. Which of the following is NOT a typical feature of this patient&#39;s likely diagnosis?</span></span></p>",
      "unique_key": "Q2333856",
      "question_audio": null,
      "question_video": null,
      "map_id": 20085,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Decreased residual volume (RV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD is characterized by air trapping, which leads to an <em>increased</em> residual volume (RV).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Irreversible airflow limitation:</span></strong><span style=\"font-size:12.0pt\"> This is the hallmark of COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Affects small airways:</span></strong><span style=\"font-size:12.0pt\"> Small airway inflammation and narrowing contribute to COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Can occurs due to protease-antiprotease imbalance:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This imbalance contributes to the destruction of lung tissue in emphysema, which is a major cause of COPD</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD is characterized by air trapping, leading to an increased residual volume (RV), not decreased.</span></span></p>",
      "correct_choice_id": 80570,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20153,
      "choices": [
        {
          "id": 80573,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Centrilobular emphysema </span></span></span></p>"
        },
        {
          "id": 80574,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Paraseptal emphysema </span></span></span></p>"
        },
        {
          "id": 80575,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panacinar emphysema </span></span></span></p>"
        },
        {
          "id": 80576,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bullous emphysema</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with alpha-1 antitrypsin deficiency is found to have emphysema predominantly affecting the lower lobes of the lungs. Which type of emphysema is this most consistent with?</span></span></p>",
      "unique_key": "Q6189477",
      "question_audio": null,
      "question_video": null,
      "map_id": 20086,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Panacinar emphysema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panacinar emphysema involves uniform destruction of the acinus (respiratory bronchiole, alveolar ducts, and alveoli) and is typically seen in the lower lobes of patients with alpha-1 antitrypsin deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Centrilobular emphysema:</span></strong><span style=\"font-size:12.0pt\"> Predominantly affects the respiratory bronchioles and is more common in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Paraseptal emphysema:</span></strong><span style=\"font-size:12.0pt\"> Occurs adjacent to pleural surfaces and interlobular septa.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bullous emphysema:</span></strong><span style=\"font-size:12.0pt\"> Refers to large bullae formation, not a distinct type.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Panacinar emphysema involves uniform destruction of the acinus and is typically seen in the lower lobes of patients with alpha-1 antitrypsin deficiency.</span></span></p>",
      "correct_choice_id": 80575,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20154,
      "choices": [
        {
          "id": 80577,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce mortality in COPD </span></span></span></p>"
        },
        {
          "id": 80578,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the frequency of COPD exacerbations. </span></span></span></p>"
        },
        {
          "id": 80579,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the rate of decline of FEV1 in COPD</span></span></span></p>"
        },
        {
          "id": 80580,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the incidence of pneumonia in COPD.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with moderate to severe COPD is being considered for treatment with inhaled corticosteroids (ICS). Which of the following statements is TRUE regarding the use of ICS in COPD?</span></span></span></p>",
      "unique_key": "Q6084969",
      "question_audio": null,
      "question_video": null,
      "map_id": 20087,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) ICS reduce the frequency of COPD exacerbations.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While ICS don&#39;t reduce mortality or slow FEV1 decline in COPD, they have been shown to reduce the frequency of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ICS reduce mortality in COPD</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Not true. But recently, triple combinations (LABA + LAMA + ICS) in selected patients (Group E) has shown to reduce mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ICS reduce the rate of decline of FEV1 in COPD</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Not true.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ICS reduce the incidence of pneumonia in COPD</strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Actually, ICS may slightly increase the risk of pneumonia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhaled corticosteroids (ICS) reduce the frequency of COPD exacerbations.</span></span></p>",
      "correct_choice_id": 80578,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20155,
      "choices": [
        {
          "id": 80581,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daily azithromycin 500mg </span></span></span></p>"
        },
        {
          "id": 80582,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous oxygen at 2 L/min </span></span></span></p>"
        },
        {
          "id": 80583,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nocturnal BiPAP (bilevel positive airway pressure) </span></span></span></p>"
        },
        {
          "id": 80584,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled corticosteroids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 69-year-old smoker with COPD has had three hospitalizations for exacerbations in the past year. He is already on LABA(long acting beta 2 agonist), LAMA long acting muscarinic antagonist) and ICS (inhaled corticosteroids). Which of the following treatments is most likely to decrease the frequency of his exacerbations?</span></span></span></p>",
      "unique_key": "Q2999796",
      "question_audio": null,
      "question_video": null,
      "map_id": 20088,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Daily azithromycin 500mg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has severe COPD with frequent exacerbations despite being on triple therapy(LABA, LAMA, and ICS). In such cases, studies have shown that daily azithromycin 250mg or 500mg can significantly reduce the frequency of exacerbations due to its anti-inflammatory and immunomodulatory effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Continuous oxygen at 2 L/min:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While oxygen therapy is crucial for patients with chronic hypoxemia,&nbsp;it doesn&#39;t directly reduce the frequency of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nocturnal BiPAP (bilevel positive airway pressure)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is indicated for COPD patients with hypercapnic respiratory failure or nocturnal desaturation,&nbsp;not as a primary prevention for exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhaled corticosteroids:</span></strong><span style=\"font-size:12.0pt\">&nbsp;The patient is already on ICS,&nbsp;and further increasing the dose is unlikely to provide additional benefit in preventing exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Daily azithromycin 500mg can significantly reduce the frequency of exacerbations in severe COPD patients already on LABA, LAMA, and ICS therapy.</span></span></span></p>",
      "correct_choice_id": 80581,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20156,
      "choices": [
        {
          "id": 80585,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoxemia (PaO2 &lt; 60 mmHg on room air) </span></span></span></p>"
        },
        {
          "id": 80586,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypercapnia (PaCO2 &gt; 50 mmHg) </span></span></span></p>"
        },
        {
          "id": 80587,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Respiratory acidosis (pH &lt; 7.35) </span></span></span></p>"
        },
        {
          "id": 80588,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inability to protect airway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with an acute exacerbation of COPD presents with respiratory distress, tachypnea, and altered mental status. Which of the following would be an absolute contraindication to initiating non-invasive ventilation (NIV)?</span></span></span></p>",
      "unique_key": "Q7093952",
      "question_audio": null,
      "question_video": null,
      "map_id": 20089,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Inability to protect airway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired consciousness and inability to protect the airway are absolute contraindications to NIV, as they increase the risk of aspiration and respiratory arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypoxemia (PaO2 &lt; 60 mmHg on room air):</span></strong><span style=\"font-size:12.0pt\"> NIV can be used to improve oxygenation in COPD exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><strong><span style=\"font-size:12.0pt\"> Hypercapnia (PaCO2 &gt; 50 mmHg):</span></strong><span style=\"font-size:12.0pt\"> NIV can improve ventilation and reduce CO2 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Respiratory acidosis (pH &lt; 7.35):</span></strong><span style=\"font-size:12.0pt\"> NIV can help correct acidosis caused by hypercapnia.</span></span></span></p>\r\n\r\n<div>\r\n<div>\r\n<div class=\"msocomtxt\" id=\"_com_1\">\r\n<p>&nbsp;</p>\r\n</div>\r\n</div>\r\n</div>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inability to protect the airway is an absolute contraindication to initiating non-invasive ventilation (NIV) in patients with acute exacerbation of COPD.</span></span></span></p>",
      "correct_choice_id": 80588,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20157,
      "choices": [
        {
          "id": 80589,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asthma </span></span></span></p>"
        },
        {
          "id": 80590,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD (Chronic Obstructive Pulmonary Disease) </span></span></span></p>"
        },
        {
          "id": 80591,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Preserved Ratio Impaired Spirometry (PRISm) </span></span></span></p>"
        },
        {
          "id": 80592,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal lung function</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old occasional smoker presents with a chronic cough and dyspnea on exertion. Physical examination is unremarkable, and chest X-ray is normal. Spirometry reveals an FEV1 of 60% predicted and an FEV1/FVC ratio of 80%. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8218879",
      "question_audio": null,
      "question_video": null,
      "map_id": 20090,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Preserved Ratio Impaired Spirometry (PRISm)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PRISm is characterized by reduced FEV1 but a normal FEV1/FVC ratio. It&#39;s a potential precursor to COPD, particularly in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Asthma:</span></strong><span style=\"font-size:12.0pt\"> Usually shows a reduced FEV1/FVC ratio with reversibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD (Chronic Obstructive Pulmonary Disease)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Requires an FEV1/FVC &lt; 0.70.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Normal lung function:</span></strong><span style=\"font-size:12.0pt\"> Not possible with reduced FEV1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRISm (Preserved Ratio Impaired Spirometry) is characterized by a reduced FEV1 with a normal FEV1/FVC ratio, often seen as a potential precursor to COPD.</span></span></p>",
      "correct_choice_id": 80591,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20158,
      "choices": [
        {
          "id": 80593,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, epinephrine is indicated for all asthma exacerbations. </span></span></span></p>"
        },
        {
          "id": 80594,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, but only if she fails to respond to inhaled bronchodilators. </span></span></span></p>"
        },
        {
          "id": 80595,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, epinephrine is only indicated for asthma associated with anaphylaxis or angioedema. </span></span></span></p>"
        },
        {
          "id": 80596,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, epinephrine should only be used in patients with severe asthma exacerbations requiring hospitalization.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a history of asthma presents with worsening wheezing, cough, and shortness of breath. There is no associated angioedema or urticaria. Her vital signs are stable, and her oxygen saturation is 94% on room air. Would intramuscular epinephrine be indicated in this scenario? </span></span></p>",
      "unique_key": "Q9753285",
      "question_audio": null,
      "question_video": null,
      "map_id": 20091,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">C) No, epinephrine is only indicated for asthma associated with anaphylaxis or angioedema.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intramuscular epinephrine is primarily reserved for asthma exacerbations that are accompanied by anaphylaxis or angioedema (severe allergic reactions). In this patient with no signs of anaphylaxis or angioedema, standard asthma treatment with bronchodilators and corticosteroids would be appropriate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Yes, epinephrine is indicated for all asthma exacerbations:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;Epinephrine is a potent drug reserved for life-threatening situations like anaphylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Yes, but only if she fails to respond to inhaled bronchodilators:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;While epinephrine may be used in refractory cases,&nbsp;it&#39;s not the initial therapy for most asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No, epinephrine should only be used in patients with severe asthma exacerbations requiring hospitalization:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;While epinephrine is often used in severe cases,&nbsp;it&#39;s indicated for any asthma exacerbation with anaphylaxis or angioedema,&nbsp;regardless of severity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intramuscular epinephrine is only indicated for asthma exacerbations associated with anaphylaxis or angioedema.</span></span></p>",
      "correct_choice_id": 80595,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20159,
      "choices": [
        {
          "id": 80597,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Short-acting beta-agonist (SABA) alone </span></span></span></p>"
        },
        {
          "id": 80598,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Short-acting muscarinic antagonist (SAMA) alone </span></span></span></p>"
        },
        {
          "id": 80599,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose ICS + SABA combination </span></span></span></p>"
        },
        {
          "id": 80600,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose ICS + LABA (long-acting beta-agonist) combination</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman with mild persistent asthma is well-controlled on a low-dose inhaled corticosteroid (ICS) as maintenance therapy. She experiences occasional wheezing and shortness of breath, especially after exercise. According to current asthma guidelines, which of the following is the preferred reliever medication for her symptoms?</span></span></span></p>",
      "unique_key": "Q7268981",
      "question_audio": null,
      "question_video": null,
      "map_id": 20092,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Low-dose ICS + LABA (long-acting beta-agonist) combination</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Current guidelines recommend using a combination inhaler containing both low-dose ICS and a LABA as the preferred reliever medication for ALL patients with asthma, regardless of severity. This approach provides both rapid symptom relief (LABA) and anti-inflammatory effects (ICS), reducing the risk of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Short-acting beta-agonist (SABA) alone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Although SABAs provide quick relief,&nbsp;they don&#39;t address underlying inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Short-acting muscarinic antagonist (SAMA) alone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Less effective than SABAs in most cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Low-dose ICS + SABA combination</span></strong><span style=\"font-size:12.0pt\">: Not preferred as the LABA component is short-acting and doesn&#39;t provide sustained bronchodilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The preferred reliever medication for mild persistent asthma is a combination inhaler containing both low-dose ICS and a LABA.</span></span></span></p>",
      "correct_choice_id": 80600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20160,
      "choices": [
        {
          "id": 80601,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled short-acting beta-agonists (SABA) as needed </span></span></span></p>"
        },
        {
          "id": 80602,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial thermoplasty </span></span></span></p>"
        },
        {
          "id": 80603,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-IgE therapy (e.g., omalizumab) </span></span></span></p>"
        },
        {
          "id": 80604,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral corticosteroids at higher doses</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 20-year-old man with severe asthma remains symptomatic despite high-dose inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA), and long-acting beta-agonists (LABA). He is also on oral steroids and montelukast. Further evaluation reveals elevated IgE levels and FeNO (fractional exhaled nitric oxide) of 55 ppb. Which therapy is most likely to be effective for this patient?</span></span></span></p>",
      "unique_key": "Q4471855",
      "question_audio": null,
      "question_video": null,
      "map_id": 20093,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-IgE therapy (e.g., omalizumab)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated IgE and FeNO suggest atype 2 inflammatory response. Anti-IgE therapy targets this pathway and is indicated in severe allergic asthma not controlled with standard therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><strong><span style=\"font-size:12.0pt\">Inhaled short-acting beta-agonists (SABA) as needed: &nbsp;</span></strong><span style=\"font-size:12.0pt\">Used for quick relief, not long-term control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bronchial thermoplasty:</span></strong><span style=\"font-size:12.0pt\"> Considered for severe refractory asthma but not the first-line option in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Oral corticosteroids at higher doses:</span></strong><span style=\"font-size:12.0pt\"> Already on high doses, increasing further may lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-IgE therapy (e.g., omalizumab) is indicated for severe allergic asthma not controlled with standard therapy, especially in the presence of elevated IgE and FeNO levels.</span></span></p>",
      "correct_choice_id": 80603,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20161,
      "choices": [
        {
          "id": 80605,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen therapy to maintain SpO2 &ge; 94% </span></span></span></p>"
        },
        {
          "id": 80606,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeated doses of nebulized salbutamol</span></span></span></p>"
        },
        {
          "id": 80607,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral prednisolone </span></span></span></p>"
        },
        {
          "id": 80608,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled Formeterol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old boy with a history of mild persistent asthma is brought to the ER with an acute exacerbation. His symptoms include wheezing, shortness of breath, and cough. He is using accessory muscles to breathe, and his peak flow is 50% of his personal best. Which of the following is NOT recommended as part of his initial management?</span></span></p>",
      "unique_key": "Q1042199",
      "question_audio": null,
      "question_video": null,
      "map_id": 20094,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Inhaled Formeterol</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LABAs (formeterol) are not used in the acute management of asthma exacerbations. They are long-term control medications and have a delayed onset of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oxygen therapy to maintain SpO2 &ge; 94%:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Essential to correct hypoxemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Repeated doses of nebulized salbutamol:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Mainstay of acute bronchodilator therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oral prednisolone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Oral corticosteroids reduce airway inflammation and are important in exacerbation management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LABAs like formoterol are not used in the acute management of asthma exacerbations due to their delayed onset of action.</span></span></span></p>",
      "correct_choice_id": 80608,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49955,
      "choices": [
        {
          "id": 199379,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nasal congestion</span></span></p>"
        },
        {
          "id": 199380,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Difficulty inhaling</span></span></p>"
        },
        {
          "id": 199381,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Claustrophobia</span></span></p>"
        },
        {
          "id": 199382,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aerophagia</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are complications of CPAP therapy in OSA except:</span></span></p>",
      "unique_key": "Q5871836",
      "question_audio": null,
      "question_video": null,
      "map_id": 24909,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B)&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Difficulty inhaling</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) can have several common complications, including nasal congestion, claustrophobia, aerophagia, bruised nose and difficulty exhaling. However, difficulty inhaling is not typically associated with CPAP therapy, as the therapy is designed to provide continuous positive pressure to keep the airways open, which should facilitate, rather than impede, inspiration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nasal congestion:</span></strong><span style=\"font-size:12.0pt\"> Common due to the air pressure and can be mitigated with humidification or steroid/saline nasal sprays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Claustrophobia:</span></strong><span style=\"font-size:12.0pt\"> A common issue due to the mask, which can make some patients feel confined. Can mitigate by changing mask interface (e.g., nasal prongs)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Aerophagia:</span></strong><span style=\"font-size:12.0pt\"> Swallowing air, which can lead to bloating and discomfort, is a known side effect of CPAP therapy. Can mitigate to some extent by administering antacids</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Difficulty inhaling is not a typical complication of CPAP therapy; common issues include nasal congestion, claustrophobia, and aerophagia.</span></span></span></p>",
      "correct_choice_id": 199380,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49934,
      "choices": [
        {
          "id": 199295,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate noninvasive positive pressure ventilation (NIPPV) </span></span></span></p>"
        },
        {
          "id": 199296,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start intravenous (IV) methylprednisolone </span></span></span></p>"
        },
        {
          "id": 199297,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer a nebulized bronchodilator </span></span></span></p>"
        },
        {
          "id": 199298,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proceed with endotracheal intubation (ETT) and mechanical ventilation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a history of severe COPD presents to the emergency department with an acute exacerbation. He is tachypneic, using accessory muscles of respiration, and his oxygen saturation is 88% on room air. Arterial blood gas analysis shows a pH of 7.28 and PaCO2 of 65 mmHg. Which of the following is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q6167798",
      "question_audio": null,
      "question_video": null,
      "map_id": 24889,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Initiate noninvasive positive pressure ventilation (NIPPV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is experiencing an acute exacerbation of COPD with significant hypercapnia and respiratory acidosis. NIPPV is the preferred initial management strategy in this scenario, as it can improve ventilation, reduce work of breathing, and potentially avoid the need for invasive mechanical ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Start IV methylprednisolone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Corticosteroids are indicated in COPD exacerbations,&nbsp;but NIPPV should be prioritized in patients with respiratory failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer a nebulized bronchodilator:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Bronchodilators are important for symptom relief,&nbsp;but they won&#39;t address the primary issue of hypercapnia and acidosis.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Proceed with endotracheal intubation (ETT) and mechanical ventilation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While intubation may be necessary if NIPPV fails or the patient deteriorates,&nbsp;it is not the first-line treatment due to its associated risks and complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate noninvasive positive pressure ventilation (NIPPV) for patients with acute COPD exacerbation and respiratory failure to improve ventilation and avoid invasive mechanical ventilation.</span></span></p>",
      "correct_choice_id": 199295,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InstrumentsBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49935,
      "choices": [
        {
          "id": 199299,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peak flow meter </span></span></span></p>"
        },
        {
          "id": 199300,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spirometer </span></span></span></p>"
        },
        {
          "id": 199301,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Body plethysmograph </span></span></span></p>"
        },
        {
          "id": 199302,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Incentive spirometer</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young patient with asthma is given a device to monitor his asthma. What is the device?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture5.jpg\" style=\"height:182px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q6447540",
      "question_audio": null,
      "question_video": null,
      "map_id": 24890,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Peak flow meter</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A peak flow meter is a portable device used by asthmatics to measure how fast they can forcefully exhale, providing a quick assessment of airway obstruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Spirometer:</span></strong><span style=\"font-size:12.0pt\"> Measures lung volumes and flow rates during forced exhalation and inhalation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-left:24px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture6.jpg\" style=\"height:285px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Body plethysmograph:</span></strong><span style=\"font-size:12.0pt\"> Measures total lung capacity and airway resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture7.jpg\" style=\"height:410px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Incentive spirometer:</span></strong><span style=\"font-size:12.0pt\"> Helps improve lung function by encouraging deep breaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-left:24px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture8.jpg\" style=\"height:321px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dveice shown in the image is a peak flow meter used by asthmatics to measure how fast they can forcefully exhale, providing a quick assessment of airway obstruction.</span></span></span></p>",
      "correct_choice_id": 199299,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49936,
      "choices": [
        {
          "id": 199303,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amoxicillin </span></span></span></p>"
        },
        {
          "id": 199304,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azithromycin </span></span></span></p>"
        },
        {
          "id": 199305,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Piperacillin-tazobactam </span></span></span></p>"
        },
        {
          "id": 199306,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxycycline</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old patient with known bronchiectasis is hospitalized with acute worsening of cough, sputum production, and fever. Which antibiotic regimen is most appropriate for this exacerbation?</span></span></p>",
      "unique_key": "Q6980077",
      "question_audio": null,
      "question_video": null,
      "map_id": 24891,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Piperacillin-tazobactam</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><em><span style=\"font-size:12.0pt\">Pseudomonas aeruginosa</span></em><span style=\"font-size:12.0pt\"> is a common pathogen in bronchiectasis exacerbations. Piperacillin-tazobactam is a broad-spectrum antibiotic with activity against Pseudomonas and other gram-negative organisms, making it the preferred initial therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amoxicillin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Not effective against&nbsp;<em>Pseudomonas</em>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Azithromycin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;May be used in chronic management but not first-line for acute exacerbations with Pseudomonas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Doxycycline:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Not effective against Pseudomonas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Piperacillin-tazobactam is the preferred antibiotic for acute exacerbations of bronchiectasis due to its broad-spectrum activity against Pseudomonas aeruginosa and other gram-negative organisms.</span></span></p>",
      "correct_choice_id": 199305,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49937,
      "choices": [
        {
          "id": 199307,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cylindrical bronchiectasis </span></span></span></p>"
        },
        {
          "id": 199308,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Varicose bronchiectasis </span></span></span></p>"
        },
        {
          "id": 199309,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cystic bronchiectasis </span></span></span></p>"
        },
        {
          "id": 199310,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Traction bronchiectasis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with chronic cough and sputum production undergoes bronchoscopy, which reveals dilated airways and nodular lesions. Bronchial washings culture positive for <em>Mycobacterium avium complex</em> (MAC). Which type of bronchiectasis is most likely associated?</span></span></p>",
      "unique_key": "Q6067357",
      "question_audio": null,
      "question_video": null,
      "map_id": 24892,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Varicose bronchiectasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Varicose bronchiectasis, with irregular airway dilation and constriction, is commonly seen in NTM infections like MAC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cylindrical bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This type of bronchiectasis is characterized by uniformly dilated airways, typically seen in post-infectious bronchiectasis or bronchiectasis associated with bronchial obstruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cystic bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is the most severe form of bronchiectasis, with large, balloon-like dilations of the airways. While it can be seen in NTM infections, it&#39;s less common than varicose bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Traction bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This type is caused by fibrosis pulling on the airways, often seen in conditions like tuberculosis or sarcoidosis. It presents with irregular dilations and distortions of the airways but is less common in NTM infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key Point:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Varicose bronchiectasis is the most common type seen in NTM infections, particularly <em>Mycobacterium avium</em> complex (MAC). The irregular dilations and constrictions of the airways resemble varicose veins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Varicose bronchiectasis, with irregular airway dilation and constriction, is commonly seen in NTM infections like Mycobacterium avium complex (MAC).</span></span></span></p>",
      "correct_choice_id": 199308,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49938,
      "choices": [
        {
          "id": 199311,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchiectasis</span></span></p>"
        },
        {
          "id": 199312,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic bronchitis</span></span></p>"
        },
        {
          "id": 199313,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration pneumonia</span></span></p>"
        },
        {
          "id": 199314,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emphysema</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 66-year-old man presented after coughing up copious amounts of blood-tinged sputum at his nursing home Physical examination shows digital clubbing and cyanosis of the lips. Coarse crackles are heard throughout the lung fields and his SpO2 is 95%. A chest X-ray reveals increased translucency and tram-track opacities in the right lower lung field. What is the likely diagnosis?</span></span></span></p>",
      "unique_key": "Q1729612",
      "question_audio": null,
      "question_video": null,
      "map_id": 24893,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Bronchiectasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with typical symptoms of bronchiectasis, including chronic cough with copious amounts of sputum, hemoptysis, and coarse crackles on auscultation. The presence of tram-track opacities on the chest X-ray is characteristic of bronchiectasis, indicating thickened bronchial walls. Digital clubbing and cyanosis are also associated with chronic hypoxia commonly seen in bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Chronic bronchitis:</span></strong><span style=\"font-size:12.0pt\"> Typically seen in patients with a history of smoking and characterized by a chronic, productive cough. However, copious amounts of blood-tinged sputum and signs of chronic hypoxia (e.g., digital clubbing, lip cyanosis) are less typical.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Aspiration pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Common in patients with a history of stroke, which may result in dysphagia. Patients with aspiration pneumonia may present with dyspnea, cough, and hypoxemia, but would not typically show the tram-track opacities seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Emphysema:</span></strong><span style=\"font-size:12.0pt\"> Usually presents with a history of a chronic cough that is characteristically worse in the mornings, production of small amounts of sputum, and dyspnea. Chest X-rays typically show hyperinflation rather than tram-track opacities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchiectasis presents with chronic cough, copious sputum, hemoptysis, coarse crackles, and tram-track opacities on X-ray, along with digital clubbing and cyanosis due to chronic hypoxia.</span></span></span></p>",
      "correct_choice_id": 199311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49939,
      "choices": [
        {
          "id": 199315,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cirrhosis</span></span></p>"
        },
        {
          "id": 199316,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypothyroidism</span></span></p>"
        },
        {
          "id": 199317,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Panacinar emphysema</span></span></p>"
        },
        {
          "id": 199318,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancreatitis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 4-year-old girl presents with productive cough, high fever, poor weight gain, and frequent respiratory infections. Exam reveals crackles in the left lower lung. Chest X-ray shows dilated bronchi and infiltrates. Sputum culture: pink rods on Gram stain, non-lactose fermenting, oxidase positive. She is at increased risk for which condition?</span></span></span></p>",
      "unique_key": "Q3080617",
      "question_audio": null,
      "question_video": null,
      "map_id": 24894,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pancreatitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms and findings suggest cystic fibrosis (CF), which is characterized by thick mucus secretions that lead to chronic respiratory infections and bronchiectasis. The bacteria identified, likely Pseudomonas aeruginosa, is common in CF patients. CF also affects the pancreas, leading to an increased risk of pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cirrhosis:</span></strong><span style=\"font-size:12.0pt\"> &nbsp;Although CF can lead to liver disease, pancreatitis is a more immediate and common complication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Not typically associated with CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Panacinar emphysema:</span></strong><span style=\"font-size:12.0pt\"> More commonly related to alpha-1 antitrypsin deficiency, not CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystic fibrosis, characterized by chronic respiratory infections and bronchiectasis, increases the risk of pancreatitis due to thick mucus secretions affecting the pancreas.</span></span></p>",
      "correct_choice_id": 199318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49940,
      "choices": [
        {
          "id": 199319,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemoptysis</span></span></p>"
        },
        {
          "id": 199320,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rhizopus infections</span></span></p>"
        },
        {
          "id": 199321,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumothorax</span></span></p>"
        },
        {
          "id": 199322,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old man complains of cough, shortness of breath, and daily copious sputum production. He has a history of frequent lung infections. His SpO2 is 95%. Diffuse crackles and wheezing are heard on auscultation throughout the lung fields. A CT scan is shown. The patient is at greatest risk for which of the following complications?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture9.jpg\" style=\"height:264px; width:300px\" /></span></span></p>",
      "unique_key": "Q1126361",
      "question_audio": null,
      "question_video": null,
      "map_id": 24895,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hemoptysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history and CT findings suggest bronchiectasis, characterized by chronic productive cough and recurrent lung infections. One of the most significant complications of bronchiectasis is hemoptysis due to damage and dilation of the bronchial arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Rhizopus infections:</span></strong><span style=\"font-size:12.0pt\"> Causes Mucormycosis. Uncommon in bronchiectasis. More common in patients with DKA or COVID19</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pneumothorax:</span></strong><span style=\"font-size:12.0pt\"> While possible, it is less common in bronchiectasis. More common in Emphysema</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung cancer:</span></strong><span style=\"font-size:12.0pt\"> Bronchiectasis is not a risk factor for lung cancer </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchiectasis, characterized by chronic productive cough and recurrent lung infections, significantly increases the risk of hemoptysis due to damage and dilation of the bronchial arteries.</span></span></span></p>",
      "correct_choice_id": 199319,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49941,
      "choices": [
        {
          "id": 199323,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cells with multilobular nuclei and enzyme-filled granules</span></span></span></p>"
        },
        {
          "id": 199324,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Collagen &alpha;-chains in triplets</span></span></p>"
        },
        {
          "id": 199325,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heavy and light protein chains linked by disulfide bonds</span></span></p>"
        },
        {
          "id": 199326,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tubular arrangements of linked heavy chains that slide against one another</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old man with a history of upper respiratory tract infections presents with four other respiratory infections this year and frequent bouts of otitis media. He was diagnosed with bronchiectasis as a child. Which structure is most likely defective in this patient?</span></span></span></p>",
      "unique_key": "Q4223105",
      "question_audio": null,
      "question_video": null,
      "map_id": 24896,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tubular arrangements of linked heavy chains that slide against one another</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms suggest primary ciliary dyskinesia (Kartagener syndrome), where the defect is in the cilia&#39;s dynein arms. These are tubular arrangements of linked heavy chains that slide against one another to facilitate movement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cells with multilobular nuclei and enzyme-filled granules:</span></strong><span style=\"font-size:12.0pt\"> Refers to neutrophils, not related to this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Collagen &alpha;-chains in triplets:</span></strong><span style=\"font-size:12.0pt\"> Related to collagen structure, not relevant here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Heavy and light protein chains linked by disulfide bonds:</span></strong><span style=\"font-size:12.0pt\"> Refers to immunoglobulins, not relevant here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s symptoms suggest primary ciliary dyskinesia (Kartagener syndrome), where the defect is in the cilia&#39;s dynein arms, which are tubular arrangements of linked heavy chains that slide against one another to facilitate movement.</span></span></span></p>",
      "correct_choice_id": 199326,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49942,
      "choices": [
        {
          "id": 199327,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudomonas aeruginosa</span></span></p>"
        },
        {
          "id": 199328,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Staphylococcus aureus</span></span></p>"
        },
        {
          "id": 199329,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Haemophilus influenzae</span></span></p>"
        },
        {
          "id": 199330,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Streptococcus pneumoniae</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child with cystic fibrosis presents with a persistent cough and frequent respiratory infections over the past year. Sputum cultures have consistently grown a specific pathogen. Given the patient&#39;s age and clinical history, which pathogen is most likely responsible for these early respiratory infections?</span></span></p>",
      "unique_key": "Q1707191",
      "question_audio": null,
      "question_video": null,
      "map_id": 24897,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Staphylococcus aureus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Staphylococcus aureus is the primary pathogen responsible for early respiratory infections in cystic fibrosis patients. It frequently colonizes the respiratory tract of young children with cystic fibrosis and can cause persistent and recurrent infections, leading to inflammation and damage in the lungs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pseudomonas aeruginosa:</span></strong><span style=\"font-size:12.0pt\"> This pathogen typically becomes more prevalent in the respiratory tracts of cystic fibrosis patients as they get older and is associated with chronic lung infections and a more rapid decline in lung function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Haemophilus influenzae:</span></strong><span style=\"font-size:12.0pt\"> This bacterium can cause respiratory infections but is less common and less significant than Staphylococcus aureus in the early stages of cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Streptococcus pneumoniae:</span></strong><span style=\"font-size:12.0pt\"> Although it can cause respiratory infections, it is not the primary pathogen in early cystic fibrosis respiratory infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Staphylococcus aureus is the primary pathogen responsible for early respiratory infections in young children with cystic fibrosis, frequently causing persistent and recurrent infections.</span></span></span></p>",
      "correct_choice_id": 199328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49943,
      "choices": [
        {
          "id": 199331,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of liver dysfunction post-transplant</span></span></p>"
        },
        {
          "id": 199332,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced success rates of lung transplantation</span></span></span></p>"
        },
        {
          "id": 199333,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Higher likelihood of developing diabetes post-transplant</span></span></span></p>"
        },
        {
          "id": 199334,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of gastrointestinal complications</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 16-year-old patient with cystic fibrosis, who has been colonized with Burkholderia cepacia complex (BCC), is scheduled for a lung transplant evaluation. What is a major concern related to BCC colonization in this context?</span></span></span></p>",
      "unique_key": "Q6352765",
      "question_audio": null,
      "question_video": null,
      "map_id": 24898,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Reduced success rates of lung transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colonization with Burkholderia cepacia complex (BCC) is a significant concern in cystic fibrosis patients undergoing lung transplantation due to the increased risk of post-transplant complications and reduced success rates. BCC is highly resistant to antibiotics and can lead to severe infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased risk of liver dysfunction post-transplant:</span></strong><span style=\"font-size:12.0pt\"> This is not specifically related to BCC colonization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Higher likelihood of developing diabetes post-transplant:</span></strong><span style=\"font-size:12.0pt\"> Diabetes can occur post-transplant but is not specifically linked to BCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increased risk of gastrointestinal complications:</span></strong><span style=\"font-size:12.0pt\"> Gastrointestinal issues are common in cystic fibrosis but not specifically related to BCC colonization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkholderia cepacia complex (BCC) colonization in cystic fibrosis patients is a significant concern due to the reduced success rates and increased risk of severe infections post-lung transplantation.</span></span></span></p>",
      "correct_choice_id": 199332,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49944,
      "choices": [
        {
          "id": 199335,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10-15 mL per year</span></span></p>"
        },
        {
          "id": 199336,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20-30 mL per year</span></span></p>"
        },
        {
          "id": 199337,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50-55 mL per year</span></span></span></p>"
        },
        {
          "id": 199338,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">70-80 mL per year</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old patient with a history of non-CF bronchiectasis presents for a routine follow-up. The patient has experienced a noticeable decline in lung function over the past few years. What is the typical annual decline in FEV1 for patients with non-CF bronchiectasis?</span></span></p>",
      "unique_key": "Q6850362",
      "question_audio": null,
      "question_video": null,
      "map_id": 24899,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 50-55 mL per year</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with non-CF bronchiectasis typically experience a decline in FEV1 of about 50-55 mL per year, which is significantly higher than the decline observed in healthy individuals (20-30 mL per year). This rapid decline highlights the progressive nature of bronchiectasis and the importance of regular monitoring and management to slow disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">. <strong>10-15 mL per year:</strong> This rate is too low and more typical of normal aging in healthy individuals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 20-30 mL per year:</span></strong><span style=\"font-size:12.0pt\"> This is the decline seen in healthy controls, not in bronchiectasis patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 70-80 mL per year:</span></strong><span style=\"font-size:12.0pt\"> This rate is higher than what is typically observed in non-CF bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with non-CF bronchiectasis typically experience an annual decline in FEV1 of about 50-55 mL, highlighting the progressive nature of the disease.</span></span></p>",
      "correct_choice_id": 199337,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49945,
      "choices": [
        {
          "id": 199339,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obstruction of the epididymis</span></span></span></p>"
        },
        {
          "id": 199340,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Complete involution of the vas deferens</span></span></p>"
        },
        {
          "id": 199341,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defective spermatogenesis</span></span></p>"
        },
        {
          "id": 199342,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal imbalances</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A male patient with cystic fibrosis is found to be infertile despite having normal spermatogenesis. What is the most likely cause of this infertility?</span></span></span></p>",
      "unique_key": "Q7265437",
      "question_audio": null,
      "question_video": null,
      "map_id": 24900,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Complete involution of the vas deferens</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cystic fibrosis, nearly 99% of males are infertile due to the complete involution of the vas deferens, despite having normal spermatogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Obstruction of the epididymis:</span></strong><span style=\"font-size:12.0pt\"> Not the primary cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Defective spermatogenesis:</span></strong><span style=\"font-size:12.0pt\"> Spermatogenesis is typically normal in CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hormonal imbalances:</span></strong><span style=\"font-size:12.0pt\"> Infertility in CF is primarily due to anatomical defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cystic fibrosis, nearly 99% of males are infertile due to the complete involution of the vas deferens, despite having normal spermatogenesis.</span></span></p>",
      "correct_choice_id": 199340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49946,
      "choices": [
        {
          "id": 199343,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Appendicitis </span></span></span></p>"
        },
        {
          "id": 199344,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crohn&#39;s disease </span></span></span></p>"
        },
        {
          "id": 199345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal intestinal obstruction syndrome (DIOS) </span></span></span></p>"
        },
        {
          "id": 199346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intussusception</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old with cystic fibrosis presents with right lower quadrant abdominal pain, nausea, vomiting, and obstipation. Abdominal X-ray reveals a mass in the ileocecal region with dilated bowel loops. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q2444842",
      "question_audio": null,
      "question_video": null,
      "map_id": 24901,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Distal Intestinal Obstruction Syndrome (DIOS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal Intestinal Obstruction Syndrome (DIOS): This is a common complication in cystic fibrosis patients, caused by the buildup of thick, sticky stools in the distal ileum and cecum. The symptoms described (abdominal pain, nausea, vomiting, obstipation) and the radiological finding of a mass in the ileocecal region with dilated bowel loops are classic for DIOS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Appendicitis:</span></strong><span style=\"font-size:12.0pt\"> While appendicitis can present with similar symptoms, the presence of a mass in the ileocecal region and the patient&#39;s history of cystic fibrosis make DIOS a more likely diagnosis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Crohn&#39;s disease:</span></strong><span style=\"font-size:12.0pt\"> Crohn&#39;s disease is an inflammatory bowel disease that can cause abdominal pain and bowel obstruction. However, it is less common in cystic fibrosis patients and typically presents with a different clinical picture and radiological findings</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intussusception:</span></strong><span style=\"font-size:12.0pt\"> Intussusception is the telescoping of one segment of the intestine into another. While it can cause bowel obstruction, it is more common in children and usually presents with a sausage-shaped mass on palpation, which is not seen in this case.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal Intestinal Obstruction Syndrome (DIOS) is a common complication in cystic fibrosis, characterized by the buildup of thick, sticky stools in the distal ileum and cecum, leading to abdominal pain, nausea, vomiting, and obstipation.</span></span></span></p>",
      "correct_choice_id": 199345,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49947,
      "choices": [
        {
          "id": 199347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired synthesis of the CFTR protein</span></span></span></p>"
        },
        {
          "id": 199348,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defective chloride channel function at the cell surface</span></span></p>"
        },
        {
          "id": 199349,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased degradation of the CFTR protein in the endoplasmic reticulum</span></span></p>"
        },
        {
          "id": 199350,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abnormal post-translational modification of the CFTR protein</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old female patient with cystic fibrosis is found to have the most common mutation seen in these patients. What is the primary defect caused by this mutation?</span></span></span></p>",
      "unique_key": "Q1636120",
      "question_audio": null,
      "question_video": null,
      "map_id": 24902,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased degradation of the CFTR protein in the endoplasmic reticulum</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common mutation in cystic fibrosis is delta F508 mutation&nbsp; and this results in the misfolding of the CFTR protein, leading to its increased degradation in the endoplasmic reticulum. As a result, the defective CFTR protein fails to reach the cell surface, causing impaired chloride and water transport, which characterizes cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Impaired synthesis of the CFTR protein:</span></strong><span style=\"font-size:12.0pt\"> The delta F508 mutation affects protein folding, not synthesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Defective chloride channel function at the cell surface</span></strong><span style=\"font-size:12.0pt\">: This is a consequence, but the primary issue is the degradation before reaching the cell surface.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Abnormal post-translational modification of the CFTR protein</span></strong><span style=\"font-size:12.0pt\">: This is not the main issue with the delta F508 mutation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common mutation in cystic fibrosis, delta F508, leads to increased degradation of the CFTR protein in the endoplasmic reticulum, preventing it from reaching the cell surface and causing impaired chloride and water transport.</span></span></p>",
      "correct_choice_id": 199349,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49948,
      "choices": [
        {
          "id": 199351,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivacaftor monotherapy</span></span></p>"
        },
        {
          "id": 199352,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumacaftor/Ivacaftor combination</span></span></p>"
        },
        {
          "id": 199353,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tezacaftor/Ivacaftor combination</span></span></p>"
        },
        {
          "id": 199354,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elexacaftor/Tezacaftor/Ivacaftor combination</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old patient with cystic fibrosis has a homozygous F508del mutation in the CFTR gene. What is the most appropriate treatment regimen?</span></span></p>",
      "unique_key": "Q3804434",
      "question_audio": null,
      "question_video": null,
      "map_id": 24903,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Elexacaftor/Tezacaftor/Ivacaftor combination&nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Elexacaftor/Tezacaftor/Ivacaftor combination, known as Trikafta, is the most advanced and effective treatment for patients with the F508del mutation in the CFTR gene. This triple therapy works by correcting the folding defect (Elexacaftor and Tezacaftor) and enhancing the function of the CFTR protein at the cell surface (Ivacaftor), leading to significant improvements in lung function and other clinical outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ivacaftor monotherapy:</span></strong><span style=\"font-size:12.0pt\"> Effective for certain gating mutations but not sufficient for the F508del mutation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lumacaftor/Ivacaftor combination:</span></strong><span style=\"font-size:12.0pt\"> Provides benefit for F508del mutation but is less effective than the triple therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tezacaftor/Ivacaftor combination:</span></strong><span style=\"font-size:12.0pt\"> An improvement over Lumacaftor/Ivacaftor but still not as effective as the triple therapy for the F508del mutation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Elexacaftor/Tezacaftor/Ivacaftor combination (Trikafta) is the most advanced and effective treatment for patients with the F508del mutation in the CFTR gene.</span></span></span></p>",
      "correct_choice_id": 199354,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49949,
      "choices": [
        {
          "id": 199355,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class I mutation leading to no CFTR protein production</span></span></p>"
        },
        {
          "id": 199356,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II mutation causing defective protein processing</span></span></p>"
        },
        {
          "id": 199357,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class III mutation resulting in defective channel regulation</span></span></p>"
        },
        {
          "id": 199358,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class IV mutation causing decreased conductance</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old cystic fibrosis patient is found to have a CFTR mutation that results in defective protein processing and impaired channel function. Which type of CFTR defect is most effectively treated with a combination of potentiators and correctors?</span></span></p>",
      "unique_key": "Q2566399",
      "question_audio": null,
      "question_video": null,
      "map_id": 24904,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Class II mutation causing defective protein processing</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II CFTR mutations, such as the F508del mutation, result in defective protein processing that leads to misfolded CFTR proteins that are degraded before reaching the cell surface. This type of defect benefits from a combination of correctors and potentiators. Correctors, such as Lumacaftor or Tezacaftor, improve the folding and trafficking of the CFTR protein to the cell surface, while potentiators, such as Ivacaftor, enhance the function of the CFTR protein at the cell surface.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Class I mutation leading to no CFTR protein production:</span></strong><span style=\"font-size:12.0pt\"> These mutations produce little to no CFTR protein, making correctors and potentiators ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Class III mutation resulting in defective channel regulation</span></strong><span style=\"font-size:12.0pt\">: Typically treated effectively with potentiators alone, as the CFTR protein is present but dysfunctional.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Class IV mutation causing decreased conductance:</span></strong><span style=\"font-size:12.0pt\"> Potentiators may help, but the primary defect involves reduced channel function rather than misprocessing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II CFTR mutations causing defective protein processing are most effectively treated with a combination of correctors and potentiators.</span></span></p>",
      "correct_choice_id": 199356,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49950,
      "choices": [
        {
          "id": 199359,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoid Endotracheal intubation</span></span></p>"
        },
        {
          "id": 199360,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective intubation of the bleeding lung to remove blood clots</span></span></p>"
        },
        {
          "id": 199361,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insert a single-lumen endotracheal tube</span></span></p>"
        },
        {
          "id": 199362,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Position the patient with the bleeding side down</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old man presents with massive hemoptysis and is desaturating. Which of the following is incorrect according to AAFP guidelines?</span></span></span></p>",
      "unique_key": "Q7879192",
      "question_audio": null,
      "question_video": null,
      "map_id": 24905,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Selective intubation of the bleeding lung to remove blood clots</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B :</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to AAFP guidelines, selective intubation should be performed on the nonbleeding lung, not the bleeding lung. This helps protect the nonbleeding lung from contamination and allows effective ventilation. Avoiding endotracheal intubation is recommended unless truly necessary, and positioning the patient with the bleeding side down helps keep blood out of the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Avoid Endotracheal intubation:</span></strong><span style=\"font-size:12.0pt\"> Recommended unless absolutely necessary, to use the cough reflex for blood removal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insert a single-lumen endotracheal tube:</span></strong><span style=\"font-size:12.0pt\"> Incorrect as it does not allow for selective ventilation and protection of the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Position the patient with the bleeding side down</span></strong><span style=\"font-size:12.0pt\">: Correct as it uses gravitational advantage to prevent blood from entering the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to AAFP guidelines, selective intubation should be performed on the nonbleeding lung, not the bleeding lung, to protect the nonbleeding lung from contamination and ensure effective ventilation.</span></span></span></p>",
      "correct_choice_id": 199360,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49951,
      "choices": [
        {
          "id": 199363,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberculosis</span></span></p>"
        },
        {
          "id": 199364,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Viral bronchitis</span></span></p>"
        },
        {
          "id": 199365,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer</span></span></p>"
        },
        {
          "id": 199366,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old lady presents with non-massive hemoptysis. What is the most common cause?</span></span></p>",
      "unique_key": "Q7296196",
      "question_audio": null,
      "question_video": null,
      "map_id": 24906,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Viral bronchitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Viral bronchitis is the most common cause of non-massive hemoptysis, typically resulting from inflammation and irritation of the airways. It often presents with a productive cough and blood-tinged sputum, especially in the context of a recent or ongoing respiratory infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tuberculosis:</span></strong><span style=\"font-size:12.0pt\"> It is one of the most common causes in developing countries like India.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lung cancer:</span></strong><span style=\"font-size:12.0pt\"> A significant cause but not the most common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pulmonary embolism:</span></strong><span style=\"font-size:12.0pt\"> Can cause hemoptysis, but it is not the most common cause of non-massive hemoptysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Viral bronchitis is the most common cause of non-massive hemoptysis, typically resulting from inflammation and irritation of the airways.</span></span></span></p>",
      "correct_choice_id": 199364,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49952,
      "choices": [
        {
          "id": 199367,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchoscopy</span></span></p>"
        },
        {
          "id": 199368,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchial artery embolization</span></span></p>"
        },
        {
          "id": 199369,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Surgical resection</span></span></p>"
        },
        {
          "id": 199370,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous antibiotic therapy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old male presents with massive hemoptysis. What is the procedure of choice for controlling the bleeding?</span></span></span></p>",
      "unique_key": "Q5313482",
      "question_audio": null,
      "question_video": null,
      "map_id": 24907,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bronchial artery embolization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial artery embolization is the procedure of choice for controlling bleeding in life-threatening cases of hemoptysis as most massive bleeds originate from the bronchial circulation. This interventional radiology technique effectively targets and stops the source of bleeding, providing rapid control and stabilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bronchoscopy:</span></strong><span style=\"font-size:12.0pt\"> Useful for diagnosis and initial management but not primarily for controlling severe bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Surgical resection:</span></strong><span style=\"font-size:12.0pt\"> Considered when embolization fails or is not feasible, but it is more invasive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intravenous antibiotic therapy:</span></strong><span style=\"font-size:12.0pt\"> Used to treat underlying infections but not effective for immediate control of severe bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial artery embolization is the procedure of choice for controlling bleeding in life-threatening cases of massive hemoptysis.</span></span></span></p>",
      "correct_choice_id": 199368,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49953,
      "choices": [
        {
          "id": 199371,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></p>"
        },
        {
          "id": 199372,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stroke</span></span></p>"
        },
        {
          "id": 199373,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis</span></span></p>"
        },
        {
          "id": 199374,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiovascular disease</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are complications of obstructive sleep apnea (OSA) except:</span></span></p>",
      "unique_key": "Q1273527",
      "question_audio": null,
      "question_video": null,
      "map_id": 24908,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pulmonary fibrosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">OPtion C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obstructive sleep apnea (OSA) is associated with several complications, including hypertension, stroke, and cardiovascular disease, due to repeated episodes of hypoxia and increased sympathetic activity. Pulmonary fibrosis, however, is not a typical complication of OSA and is more commonly associated with other conditions such as chronic exposure to lung irritants or autoimmune diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Hypertension:</span></strong><span style=\"font-size:12.0pt\"> Common in OSA due to repeated hypoxic episodes and increased sympathetic activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Stroke:</span></strong><span style=\"font-size:12.0pt\"> Increased risk due to the association of OSA with hypertension and other cardiovascular risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiovascular disease:</span></strong><span style=\"font-size:12.0pt\"> Strongly linked with OSA, including conditions such as heart failure and arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis is not a typical complication of obstructive sleep apnea (OSA); common complications include hypertension, stroke, and cardiovascular disease.</span></span></p>",
      "correct_choice_id": 199373,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}